FDA Inspection 1306730 — Cagatay Arslan, M.D.
The FDA completed an inspection of Cagatay Arslan, M.D. on Feb 19, 2026 in Imbatli. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Feb 19, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Imbatli (Turkey)
Additional details
Clinical Investigator (CI)